{"id":"sorafenib-tosylate-tablets","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Hand-foot skin reaction"},{"rate":"20-30%","effect":"Hypertension"},{"rate":"10-20%","effect":"Dermatological reactions"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sorafenib Tosylate Tablets work by targeting various kinases, including RAF kinase, VEGFR, and PDGFR, which play a role in tumor growth and angiogenesis. This leads to the inhibition of tumor cell proliferation and the induction of apoptosis. Additionally, sorafenib tosylate tablets may also have anti-angiogenic effects by inhibiting the formation of new blood vessels that supply the tumor.","oneSentence":"Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:22.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Advanced hepatocellular carcinoma"},{"name":"Advanced radioactive iodine-refractory differentiated thyroid cancer"}]},"trialDetails":[{"nctId":"NCT04344158","phase":"PHASE3","title":"A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-11","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":648},{"nctId":"NCT03236649","phase":"PHASE3","title":"The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects","status":"TERMINATED","sponsor":"Beijing Shenogen Biomedical Co., Ltd","startDate":"2017-09-20","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":89},{"nctId":"NCT04326439","phase":"PHASE2","title":"AflacLL1901 (CHOA-AML)","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-24","conditions":"Acute Myeloid Leukemia, AML, Childhood","enrollment":8},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT01497444","phase":"PHASE1","title":"Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-05","conditions":"Kidney Cancer, Liver Cancer","enrollment":24},{"nctId":"NCT00869570","phase":"PHASE1, PHASE2","title":"External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2009-03","conditions":"Colorectal Cancer","enrollment":54},{"nctId":"NCT01258608","phase":"PHASE1, PHASE2","title":"Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2011-02-08","conditions":"Carcinoma, Hepatocellular","enrollment":101},{"nctId":"NCT01135056","phase":"PHASE3","title":"Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2010-07","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT00522301","phase":"PHASE2","title":"Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":6},{"nctId":"NCT00480389","phase":"PHASE2","title":"Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2007-05","conditions":"Renal Cell Carcinoma, Metastatic Disease","enrollment":19},{"nctId":"NCT01223027","phase":"PHASE3","title":"Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Metastatic Renal Cell Carcinoma","enrollment":564},{"nctId":"NCT00098254","phase":"PHASE2","title":"BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexavar"],"phase":"phase_3","status":"active","brandName":"Sorafenib Tosylate Tablets","genericName":"Sorafenib Tosylate Tablets","companyName":"Beijing Shenogen Biomedical Co., Ltd","companyId":"beijing-shenogen-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis. Used for Advanced renal cell carcinoma, Advanced hepatocellular carcinoma, Advanced radioactive iodine-refractory differentiated thyroid cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}